Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Higher-Risk Myelodysplastic Syndrome”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT04243785
What this trial is testing

BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Edgewood Oncology Inc. 80
Early research (Phase 1)Looking for participantsNCT03113643
What this trial is testing

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell Neoplasm
Dana-Farber Cancer Institute 72
Testing effectiveness (Phase 2)UnknownNCT01342692
What this trial is testing

Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes

Who this might be right for
MDS
Assistance Publique - Hôpitaux de Paris 320
Very early researchStudy completedNCT02233504
What this trial is testing

Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)

Who this might be right for
High Risk MDS or AML Patients
Abramson Cancer Center at Penn Medicine 25
Testing effectiveness (Phase 2)Study completedNCT01085838
What this trial is testing

Erlotinib in Higher Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Groupe Francophone des Myelodysplasies 30
Not applicableUnknownNCT01331603
What this trial is testing

Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis

Who this might be right for
Myelodysplastic SyndromePrimary Myelofibrosis
Wolfson Medical Center 50
Testing effectiveness (Phase 2)WithdrawnNCT02829840
What this trial is testing

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

Who this might be right for
LeukemiaFLT3-Mutated Acute Myeloid LeukemiaFLT3-Mutated High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Early research (Phase 1)Study completedNCT00807677
What this trial is testing

Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaChronic Myelogenous Leukemia+9 more
Millennium Pharmaceuticals, Inc. 31
Testing effectiveness (Phase 2)Study completedNCT03672539
What this trial is testing

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaHigh Risk Myelodysplastic Syndrome+3 more
M.D. Anderson Cancer Center 50
Early research (Phase 1)Study completedNCT01169012
What this trial is testing

PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias

Who this might be right for
Myelodysplastic SyndromeAcute Myeloid LeukemiaAcute Lymphoblastic Leukemia+1 more
UNC Lineberger Comprehensive Cancer Center 13
Early research (Phase 1)Study completedNCT03359460
What this trial is testing

Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic SyndromePreviously Treated Myelodysplastic SyndromeRefractory High Risk Myelodysplastic Syndrome+2 more
University of California, Davis 4
Early research (Phase 1)Looking for participantsNCT07384715
What this trial is testing

First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

Who this might be right for
R/R AMLR/R HR-MDSAcute Myeloid Leukemia+1 more
Genmab 78
Testing effectiveness (Phase 2)Study completedNCT00077116
What this trial is testing

Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome

Who this might be right for
LeukemiaMyelodysplastic Syndromes
European Organisation for Research and Treatment of Cancer - EORTC 31
Testing effectiveness (Phase 2)Ended earlyNCT00185679
What this trial is testing

Haploid Allogeneic Transplant Using the CliniMACS System

Who this might be right for
Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk FactorsChronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic PhaseMyelodysplastic Syndrome (MDS) - High and Intermediate Risk+2 more
Ginna Laport 13
Testing effectiveness (Phase 2)Study completedNCT04079296
What this trial is testing

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome
Astellas Pharma Global Development, Inc. 43
Testing effectiveness (Phase 2)Looking for participantsNCT07046078
What this trial is testing

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Who this might be right for
Acute Leukemia of Ambiguous LineageAcute Myeloid LeukemiaChronic Myelomonocytic Leukemia+1 more
Fred Hutchinson Cancer Center
Early research (Phase 1)Study completedNCT05829226
What this trial is testing

Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Who this might be right for
AML, Adult RecurrentMDS
PureTech 101
Testing effectiveness (Phase 2)Study completedNCT00451048
What this trial is testing

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Who this might be right for
Chronic Myelomonocytic Leukemiade Novo Myelodysplastic SyndromesMyelodysplastic Syndromes+1 more
National Cancer Institute (NCI) 10
Early research (Phase 1)Study completedNCT01757639
What this trial is testing

Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome+3 more
National Cancer Institute (NCI) 42
Early research (Phase 1)Active Not RecruitingNCT06034470
What this trial is testing

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Who this might be right for
Acute Myeloid LeukemiaMixed Phenotype Acute LeukemiaMyelodysplastic Syndrome+2 more
Fred Hutchinson Cancer Center 30
Next Page
20